Baxter's support of veterans, service members, military families and civilian partners creates meaningful benefits for the military community
Emerald Health Therapeutics Inc. announced today that it has completed its previously announced investment of $2.5 million into Northern Vine Canada Inc. to acquire 53% of the company and appoint three of its four directors.
"Cutting the NIH budget could dismantle our ability to address real problems."
Roche announced today that the US FDA approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).
The Toyota Mobility Foundation, in partnership with Nesta's Challenge Prize Centre, has launched a $4 million dollar global challenge to change the lives of people with lower-limb paralysis, culminating in the unveiling of the winners in Tokyo in 2020.
The flu can be deadly—particularly after you've fended off a serious initial infection.
FUJIFILM Corporation has announced that, on November 10, it made a 170 million yen capital investment, through a third-party share allocation, in TOKIWA-Bio, Inc., a bioventure exploring the practical application of therapeutic drugs based on new transgenic technologies
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the third quarter ended September 30, 2017
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today an operational update and financial results for the third quarter ended September 30, 2017
Roche today announced that the FDA approved the sNDA for Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2017, after the close of the U.S. financial markets on Wednesday, November 8, 2017
Intellia Therapeutics, Inc. today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $24.00 per share
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
UK: Sleepless cities revealed as one in three adults suffer from insomnia
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review